MISSION: To provide resources, information, support, and HOPE to all those who are affected by advanced or metastatic cancer.

Cancer Type

If Cancer Spreads

10,658

Say YES to HOPE

To provide information, resources, support, and HOPE to those affected by advanced or metastatic cancer.

Say YES to HOPE

1 day ago

Hope in the Sand from Billy Werner and Evie West Werner in Gulf Shores, Alabama. ... See MoreSee Less

Photo

View on Facebook

Say YES to HOPE

3 days ago

Photo

View on Facebook

Say YES to HOPE

2 weeks ago

As many of you know, Say YES to Hope supports metastatic cancer patients. During the holidays, it is tough for many families. From financial stress and being homebound to side effects and loneliness or fatigue, it is our privilege to take away some of the stress and make this season hopeful!While we have matched several families for gifts and giving this year, we have more wish lists to fill! Over the next few days, we will be posting Amazon wish lists that we want to complete. If you feel it in your heart, please choose a list and help check off some Christmas wishes!The first list is from Joanna, a stage 4 colorectal cancer patient. She lives alone and recently moved from Texas to South Carolina. She is receiving Oxaliplatin for chemotherapy and is affected by the cold. The items on her wish list will help with warmth and comfort. She will appreciate any gift you choose! Let's help fill her stocking! ... See MoreSee Less

Check out my list on Amazon

www.amazon.com

View on Facebook

Say YES to HOPE

2 weeks ago

Breaking news! 🚨 The FDA has approved niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer. Read more about the approval: ... See MoreSee Less

FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

hubs.li

FDA approves a new treatment combining niraparib and abiraterone for BRCA2-mutated metastatic prostate cancer, enhancing patient outcomes.

View on Facebook